{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/management/unconfirmed-cause/","result":{"pageContext":{"chapter":{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause","depth":2,"htmlHeader":"<!-- begin field 4d65f3dc-126f-473b-aa2b-b65d15cdeeb2 --><h2>Scenario: Hypercalcaemia - unconfirmed cause</h2><!-- end field 4d65f3dc-126f-473b-aa2b-b65d15cdeeb2 -->","summary":"Covers the management of people with hypercalcaemia of unconfirmed or unknown cause.","htmlStringContent":"<!-- begin item 9d4e36a3-b946-4f4b-b1f7-a172f2b7e462 --><!-- begin field 3592b599-e946-4b08-bf21-acbc0155cd3d --><p>From age 18 years onwards.</p><!-- end field 3592b599-e946-4b08-bf21-acbc0155cd3d --><!-- end item 9d4e36a3-b946-4f4b-b1f7-a172f2b7e462 -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4d519537-fc10-5ad0-83b5-ac02557d4dea","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 8db61a16-2e20-4dd3-a5fc-62a263b9bef6 --><h3>How should I manage a person with hypercalcaemia without a confirmed cause?</h3><!-- end field 8db61a16-2e20-4dd3-a5fc-62a263b9bef6 -->","summary":null,"htmlStringContent":"<!-- begin item b503b084-b788-42ed-9b74-7974b5aa9921 --><!-- begin field 62c0a9b6-819c-49b8-9cd1-1066e2892127 --><p><strong>The management of hypercalaemia depends on the presentation and likely underlying cause.</strong></p><ul><li><strong>If the person has </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">severe</a><strong> hypercalcaemia or severe </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">symptoms</a><strong>:</strong><ul><li>Arrange emergency admission to hospital for further <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a> such as intravenous fluids and intravenous bisphosphonate therapy (pamidronate or zoledronate).</li></ul></li><li><strong>If the person is asymptomatic or has minimal symptoms, with </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">mild or moderate</a><strong> hypercalcaemia and:</strong><ul><li>A new diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">malignancy</a> is suspected, arrange urgent referral (to be seen within 2 weeks) to an appropriate specialist, depending on clinical judgement.</li><li>Has a known malignancy which is suspected to be the underlying cause, see the Scenario on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/known-malignancy/\">Hypercalcaemia - known malignancy</a> for more information on management.</li><li>A diagnosis of primary hyperparathyroidism is suspected on the basis of <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/assessment/\">serum parathyroid hormone (PTH) results</a>, arrange referral to endocrinology for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement.</li><li>A diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">familial hypocalciuric hypercalcaemia</a> is suspected, arrange referral to endocrinology for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement.</li><li>Is taking any <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">drugs</a> that may be causative or contributory, reduce or stop them if appropriate and recheck the serum calcium at least 3 weeks after stopping the drug. If the adjusted serum calcium confirms ongoing hypercalcaemia after stopping the drug, assess for another <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">underlying cause</a> or arrange referral, depending on clinical judgement.<ul><li>If calcium-alkali syndrome is suspected, review any drugs and consider arranging hospital admission for correction of fluid and electrolyte abnormalities.</li><li>If the person is taking lithium, liaise with their mental health specialist to discuss whether to stop or reduce the lithium, monitor the serum calcium, or arrange referral to an endocrinologist.</li></ul></li><li>A diagnosis of sarcoidosis or other <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">granulomatous disease</a> is suspected, refer the person to a respiratory or other specialist, depending on disease manifestation.</li><li>A diagnosis of tuberculosis is suspected, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tuberculosis/\">Tuberculosis</a> for more information on management.</li><li>A diagnosis of acute kidney injury (AKI) is suspected, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/acute-kidney-injury/\">Acute kidney injury</a> for more information on management.</li><li>Has known end-stage renal disease (chronic kidney disease, CKD stage 4 or 5), liaise with their renal specialist for advice on ongoing management. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>A new diagnosis of CKD, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information on further assessment and management.</li><li>A diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">non-parathyroid endocrine disease</a> is suspected, arrange referral to endocrinology for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement.</li><li>Is <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">immobilized</a> with Paget's disease:<ul><li>Encourage mobilization if possible, and monitor the serum calcium concentration. See the Scenario on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/follow-up-in-primary-care/#follow-up\">Follow-up in primary care</a> for more information on follow-up monitoring.</li><li>If mobilization is not possible, or the serum calcium concentration remains increased, arrange referral to an endocrinologist, rheumatologist, or specialist in bone disease, depending on local referral pathways.</li></ul></li><li>An underlying cause is not obvious (for example, because the PTH level is normal), arrange referral to endocrinology for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement.</li></ul></li></ul><!-- end field 62c0a9b6-819c-49b8-9cd1-1066e2892127 --><!-- end item b503b084-b788-42ed-9b74-7974b5aa9921 -->","subChapters":[{"id":"59887baf-c0e2-5bd2-8b13-1ee4c71c2deb","slug":"specialist-assessment-management","fullItemName":"Specialist assessment and management","depth":4,"htmlHeader":"<!-- begin field f14311a4-edd8-4716-8b23-aa85008bf491 --><h4>Specialist assessment and management</h4><!-- end field f14311a4-edd8-4716-8b23-aa85008bf491 -->","summary":null,"htmlStringContent":"<!-- begin item 59384e84-3855-4acb-8b88-aa85008bf45c --><!-- begin field d397283f-5040-495d-a4e7-aa85008bf491 --><h5>Specialist assessment of a person with hypercalcaemia</h5><ul><li>This may include excluding underlying causes of hypercalcaemia by arranging additional tests.<ul><li>Assessment for familial hypocalciuric hypercalaemia includes 24-hour urine collection for calcium and creatinine excretion and possible genetic testing and screening of family members.</li><li>Genetic testing may also be offered if there is a family history of hypercalcaemia and/or a suspected inherited endocrinopathy associated with primary hyperparathyroidism, such as a multiple endocrine neoplasia (MEN) syndrome.</li></ul></li><li>This may include assessing for complications of hypercalcaemia by arranging additional tests.<ul><li>Urinary biochemical stone profile to assess risk of renal stones.</li><li>Renal imaging such as ultrasound, X-ray, or CT to assess for renal stones or nephrocalcinosis (deposition of calcium salts in the renal parenchyma).</li><li>X-ray imaging may show skeletal features of primary hyperparathyroidism such as resorption of the distal ends of the clavicles, subperiosteal erosions on the radial borders of the middle or distal phalanges, bone cysts, brown tumours, and pepperpot skull.</li><li>Bone mineral density by dual-energy X-ray absorptiometry (DEXA) to assess for osteoporosis. There is typically greatest reduction in bone density seen at the distal third of the radius, followed by the hip and lumbar spine.</li></ul></li></ul><h5>Parathyroid surgery for primary hyperparathyroidism</h5><ul><li>Parathyroidectomy is the only curative treatment for primary hyperparathyroidism, with cure rates of more than 98% reported in specialist centres. Referral to a parathyroid surgeon allows for pre-operative parathyroid localisation (by ultrasound or nuclear imaging) to guide the surgical approach and technique.<ul><li>Clinical indications for parathyroidectomy include a person with primary hyperparathyroidism with:<ul><li>Symptomatic disease.</li><li>Age under 50 years.</li><li>Adjusted serum calcium concentration that is 0.25 mmol/L or more above the upper limit of normal. Note: the National Institute for Health and Care Excellence (NICE) recommends an adjusted serum calcium level of 2.85 mmol/L or above.</li><li>Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m<sup>2</sup>.</li><li>Renal stones or presence of nephrocalcinosis on renal imaging; increased renal stone risk on 24-hour urine or biochemical urine analysis.</li><li>Presence of osteoporosis or vertebral or other fragility fracture.</li></ul></li><li>Clinical indications for possible conservative management of primary hyperparathyroidism include a person with:<ul><li>Asymptomatic disease.</li><li>Age 50 years or over.</li><li>Adjusted serum calcium concentration that is less than 0.25 mmol/L above the upper limit of normal.</li><li>No end-organ damage (renal stones, fragility fractures, or osteoporosis) or other co-morbidities making them unfit for surgery.</li></ul></li><li>After successful parathyroid surgery, bone density improves, and risk of fragility fractures and renal stones are reduced. Serum calcium levels are typically measured 3–6 months after surgery. Post-operative transient hypocalcaemia may develop (usually mild) in 15–30% of people, however is managed with specialist use of calcitriol and supplemental calcium.</li></ul></li></ul><h5>Conservative management of primary hyperparathyroidism if parathyroid surgery is not appropriate</h5><ul><li>If parathyroid surgery is not indicated, declined, contraindicated, or has failed, specialist management of hypercalcaemia may include:<ul><li>Cautious correction of vitamin D deficiency if appropriate.</li><li>Calcium-lowering therapy with calcitonin which can have a rapid calcium-lowering effect by inhibiting bone resorption and renal calcium reabsorption.</li><li>Calcium-lowering therapy with the calcimimetic drug cinacalcet which may reduce serum calcium concentration. It does not have an effect on bone density or hypercalciuria.</li><li>Calcium-lowering therapy with the anti-resorptive agent desunomab, which may have a role in the emergency management of severe refractory hypercalaemia and bisphosphonate-refractory hypercalaemia of malignancy.</li><li>Bisphosphonate therapy to improve bone mineral density.</li><li>Glucocorticoid therapy for vitamin D-mediated hypercalcaemia, for example caused by some granulomatous diseases or lymphoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Marcocci et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Eastell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>]</p><!-- end field d397283f-5040-495d-a4e7-aa85008bf491 --><!-- end item 59384e84-3855-4acb-8b88-aa85008bf45c -->","subChapters":[]},{"id":"10dc302c-546d-5f50-83ed-aae576233805","slug":"basis-for-recommendation-4c5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field df1095d4-1e49-46b6-879d-165165964d47 --><h4>Basis for recommendation</h4><!-- end field df1095d4-1e49-46b6-879d-165165964d47 -->","summary":null,"htmlStringContent":"<!-- begin item 4c5564e4-2ffc-4655-9bc7-22e0b291b26b --><!-- begin field e5121e8f-3a9b-4315-bd00-fabd5e84d3b7 --><p>The recommendations on management of hypercalaemia are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Hyperparathyroidism (primary): diagnosis, assessment and initial management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>], <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2017</a>], <em>Acute kidney injury: prevention, detection and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2013</a>], and <em>Chronic kidney disease in adults: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2015</a>]; the Society for Endocrinology guideline <em>Emergency management of acute hypercalcaemia in adult patients</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>], the international consensus documents <em>Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>], <em>Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Marcocci et al, 2013</a>], and <em>The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>]; an Endocrine Society clinical practice guideline <em>Paget's disease of bone</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Singer, 2014</a>], and expert opinion in review articles on hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Joshi et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>], on parathyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>], and on hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</p><h5>Arranging emergency hospital admission for severe or symptomatic hypercalcaemia</h5><ul><li>The recommendation to arrange emergency admission if the person has severe hypercalcaemia or severe symptoms is based on the fact this can be a life-threatening condition, requiring intravenous hydration and often bisphosphonate therapy (such as pamidronate and zoledronic acid) to urgently correct hypercalcaemia and reduce the risk of complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].<ul><li>Intravenous fluid therapy and correction of hypovolaemia may improve renal perfusion and restore renal function, and help urinary excretion of calcium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul></li></ul><h5>Management of mild or moderate hypercalcaemia with no or minimal symptoms</h5><ul><li>The recommendation to arrange urgent referral if malignancy is suspected is based on the NICE clinical guideline on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2017</a>].</li><li>The recommendations on when to arrange referral to an endocrinologist are based on the NICE clinical guideline on primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>] and extrapolated from the international consensus documents on management of asymptomatic primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>].<ul><li>Specialist endocrinology assessment is helpful to confirm a diagnosis of primary hyperparathyroidism, exclude other possible causes of hypercalcaemia that may present similarly (such as familial hypocalciuric hypercalcaemia), and to advise on the need for parathyroid surgery or conservative management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>].</li></ul></li><li>The recommendation to recheck serum calcium levels 3 weeks after stopping any potentially causative drug is extrapolated from expert opinion in a review article, which recommends this washout period following stopping thiazide diuretics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>]. CKS notes that this contrasts with expert opinion in an alternative review article, which recommends repeating bloods 3 months after stopping thiazide diuretics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>].</li><li>The recommendation to assess for another underlying cause or arrange specialist referral if the adjusted serum calcium level remains high after stopping the drug is pragmatic, based on what CKS considers to be good clinical practice.<ul><li>The recommendation to consider hospital admission for people with suspected calcium-alkali syndrome is based on expert opinion from review articles that correction of fluid and electrolyte abnormalities may be needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Chan et al, 1997</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Yoshizawa, 2012</a>].</li><li>The recommendation to liaise with the person's mental health specialist if they are taking lithium is based on expert opinion from a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jones and Twomey, 2009</a>].</li></ul></li><li>The recommendation to arrange specialist referral if a granulomatous disease is suspected is extrapolated from expert opinion in review articles on sarcoidosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Wu and Schiff, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Dempsey et al, 2009</a>].</li><li>The recommendation on the management of people with suspected acute kidney injury (AKI) is based on the NICE clinical guideline on AKI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2013</a>].</li><li>The recommendations on the management of people with end-stage renal disease or suspected chronic kidney disease (CKD) are based on the NICE clinical guideline on chronic kidney disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2015</a>].</li><li>The recommendations on the management of suspected non-parathyroid endocrine disease is pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendations on the management of immobilization in Paget's disease are largely pragmatic, based on what CKS considers to be good clinical practice.<ul><li>The recommendation to arrange referral if management in primary care is not possible or successful is based on the fact that hypercalcaemia in Paget's disease may be due to co-existing primary hyperparathyroidism, which should be diagnosed and initially managed by a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Singer, 2014</a>].</li></ul></li><li>The recommendation to arrange endocrinology referral if an underlying cause is not clear is based on the need for further specialist tests to identify an underlying cause where possible [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Joshi et al, 2009</a>].</li></ul><!-- end field e5121e8f-3a9b-4315-bd00-fabd5e84d3b7 --><!-- end item 4c5564e4-2ffc-4655-9bc7-22e0b291b26b -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}